Northern Trust Corp Acelrx Pharmaceuticals Inc Transaction History

Northern Trust Corp

  • $600 Billion
  • Q3 2024

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021
SELL
$1.03 - $1.7 $791,221 - $1.31 Million
-768,176 Reduced 77.8%
219,258 $302,000
Q1 2021

May 12, 2021
BUY
$1.25 - $2.77 $116,882 - $259,011
93,506 Added 10.46%
987,434 $1.68 Million
Q4 2020

Feb 11, 2021
SELL
$1.18 - $1.98 $7,395 - $12,408
-6,267 Reduced 0.7%
893,928 $1.11 Million
Q3 2020

Nov 16, 2020
SELL
$1.01 - $1.81 $55,940 - $100,250
-55,387 Reduced 5.8%
900,195 $1.28 Million
Q2 2020

Aug 14, 2020
SELL
$1.03 - $1.69 $88,643 - $145,444
-86,062 Reduced 8.26%
955,582 $1.16 Million
Q1 2020

May 14, 2020
BUY
$0.76 - $2.07 $37,107 - $101,069
48,826 Added 4.92%
1,041,644 $1.23 Million
Q4 2019

Feb 14, 2020
BUY
$1.66 - $2.4 $43,515 - $62,913
26,214 Added 2.71%
992,818 $2.1 Million
Q3 2019

Nov 13, 2019
BUY
$2.1 - $2.87 $1.42 Million - $1.94 Million
676,352 Added 233.02%
966,604 $2.13 Million
Q2 2019

Aug 13, 2019
BUY
$2.1 - $3.93 $335,462 - $627,793
159,744 Added 122.4%
290,252 $734,000
Q1 2019

May 13, 2019
SELL
$2.35 - $3.83 $3,969 - $6,468
-1,689 Reduced 1.28%
130,508 $454,000
Q4 2018

Feb 12, 2019
BUY
$2.13 - $4.8 $37,641 - $84,825
17,672 Added 15.43%
132,197 $305,000
Q3 2018

Nov 14, 2018
BUY
$2.6 - $4.6 $104,751 - $185,329
40,289 Added 54.27%
114,525 $441,000
Q2 2018

Aug 14, 2018
SELL
$2.13 - $4.2 $36,731 - $72,429
-17,245 Reduced 18.85%
74,236 $251,000
Q1 2018

May 09, 2018
BUY
$1.7 - $2.35 $58,792 - $81,272
34,584 Added 60.78%
91,481 $192,000
Q4 2017

Feb 14, 2018
BUY
$1.75 - $5.5 $3,619 - $11,374
2,068 Added 3.77%
56,897 $115,000
Q3 2017

Nov 13, 2017
BUY
$2.9 - $4.6 $159,004 - $252,213
54,829
54,829 $252,000

About ACELRX PHARMACEUTICALS INC

ACRX Quotes by TradingView
  • Ticker ACRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 7,366,600
  • Market Cap $8.32M
  • Description
  • AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed ...
More about ACRX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email